Articles published by Rondo Therapeutics

Rondo Therapeutics Doses First Patient in Phase 1 Trial of RNDO-564, a First-in-Class Co-Stimulatory Bispecific Antibody Targeting Nectin-4 in Advanced Solid Tumors

December 03, 2025

From Rondo Therapeutics

Via Business Wire

Rondo Therapeutics Publishes Preclinical Data on RNDO-564, a Novel CD28 x Nectin-4 Co-Stimulatory Bispecific Antibody for the Treatment of Bladder Cancer

April 08, 2025

From Rondo Therapeutics

Via Business Wire

Rondo Therapeutics Presents Preclinical Data at ASCO GU for its Novel CD28 x Nectin-4 Costimulatory Bispecific Antibody for Advanced Bladder Cancer

February 10, 2025

From Rondo Therapeutics

Via Business Wire

Rondo Therapeutics Announces Collaboration with Lilly to Develop Novel CD28 Bispecific Antibodies for Solid Tumors

December 04, 2024

From Rondo Therapeutics

Via Business Wire

Thomas Manley, M.D. Joins Rondo Therapeutics as Chief Medical Officer to Lead Clinical Development of Rondo Therapeutics’ Bispecific Antibody Programs

November 19, 2024

From Rondo Therapeutics

Via Business Wire

Steven James, Accomplished CEO and Biotech Executive, Joins Board of Directors of Rondo Therapeutics

July 02, 2024

From Rondo Therapeutics

Via Business Wire

Rondo Therapeutics to Showcase Next-Generation CD28 Bispecific Platform at Upcoming Therapeutic Antibody Conferences

May 15, 2024

From Rondo Therapeutics

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.